E.g., 11/27/2024
E.g., 11/27/2024

U.S. FDA Recommends bioMérieux's VIDAS® Staphylococcal Enterotoxin Assay (SET2) as Primary Screening Method for Food Safety Testing

26 May, 2011

bioMérieux, a world leader in the field of in vitro diagnostics, announced today that the VIDAS® Staphylococcal enterotoxins assay (SET2) has been included in the United States Food and Drug Administration’s (FDA) Bacteriological Analytical Manual (BAM) for food safety testing. The FDA’s BAM is recommending that the VIDAS SET2 protocol be used as the primary screening method for the presence of Staphylococcal enterotoxins in suspect food samples and culture isolates.

bioMérieux Receives FDA Clearance for NucliSENS® EasyQ MRSA, Automated, Rapid Molecular Screening Unit

24 May, 2011

Company Offers Most Comprehensive, Cost-Effective Suite of Solutions to Detect and Screen for Methicillin Resistant Staphylococcus aureus (MRSA)

bioMérieux Presents 2011 Sonnenwirth Award for Leadership in Clinical Microbiology to Melvin Weinstein

23 May, 2011

bioMérieux, a world leader in the field of in vitro diagnostics, is proud to announce Melvin Weinstein, M.D., as the 2011 recipient of the bioMérieux Sonnenwirth Award for Leadership in Clinical Microbiology.

bioMérieux Becomes the World Leader in Food Testing with AES Laboratoire Acquisition

20 May, 2011

bioMérieux, a world leader in the field of in vitro diagnostics, has signed an agreement to acquire AES Laboratoire, a leading French group, specialized in industrial microbiological control, for 183 million euros. This will be bioMérieux’s ninth acquisition in five years and its third in the area of industrial applications.

FDA Clears First Test for Recent Infection with Toxoplasmosis Parasite

18 May, 2011

On May 18, the U.S. Food and Drug Administration cleared the first test to help determine whether a pregnant woman or a person with swollen lymph nodes testing positive for toxoplasmosis, developed the infection within the past four months.

First-Quarter 2011 Business Review

21 April, 2011

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2011. Net sales for the period reached €328 million, up a reported 6.8% from €307 million in first-quarter 2010. Growth amounted to 3.5% like-for-like (at constant exchange rates and scope of consolidation).

bioMérieux Achieves 100th PREVI® ISOLA Milestone, Installing its Automated Plate Streaker at Grady Health System

12 April, 2011

Innovative system designed by microbiologists for microbiologists helps a growing number of labs achieve substantial productivity gains.

bioMérieux Results 2010

08 March, 2011

The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met today and approved the consolidated financial statements for the year ended December 31, 2010. The meeting was chaired by Jean-Luc Bélingard and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors will be issuing an unqualified opinion in the coming days.

Ipsen and bioMérieux Enter into a Broad Partnership in Personalized Medicine

25 February, 2011

The two companies leverage combined expertise in therapeutics and in diagnostics to improve patient care

Philips and bioMérieux Announce Milestone in the Development of Innovative Handheld Diagnostic Solutions for Rapid Point-of-Care Testing

27 January, 2011

Combination of Philips’ Magnotech technology and bioMérieux’s assay technology achieves the performance requirements of rapid diagnostic testing in point-of-care applications

Pioneering Diagnostics